More News! Novartis is going for EMA Approval for CAR-T Therapy

Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

  • Allergan has returned development rights to Heptares for its muscarinic M1 agonist designed to treat Lewy body-based dementia.
  • In a secret deal, Oxford BioDynamics has a new “major US pharma” partner.
  • French spinout Dynacure licensed a drug for centronuclear myopathy from Ionis.

  • Novartis is looking for EMA approval of Kymriah, its recently FDA-approved CAR-T therapy.
  • Nordic Nanovector amended its protocol to continue with its Phase II trial for its mAb Betalutin in the UK.
  • ReNeuron also received approval to move its retinal disease candidate forward into Phase II.
  • Adaptimmune reported early-stage positive results for its SPEAR T-Cell therapy.

Images from Marco Diaz Segura, FACTORYPIC, Tilo G



Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.